[Asia Economy, reporter Yoo Hyunseok] GC Green Cross Cell is showing strong performance. The news that it has submitted an Investigational New Drug (IND) application for a Phase 3 clinical trial of Immuncell-LC for pancreatic cancer to the Ministry of Food and Drug Safety appears to be impacting its stock price.
As of 2:03 p.m. on July 6, GC Green Cross Cell was trading at 44,800 won, up 7.43% (3,100 won) from the previous trading day.
The Phase 3 clinical trial for pancreatic cancer is a commercial clinical trial aimed at adding a new indication for Immuncell-LC. The goal is to evaluate the efficacy and safety of Immuncell-LC in combination with gemcitabine, compared to gemcitabine monotherapy, which is the standard treatment, in 454 patients with pancreatic cancer.
The objective of this clinical trial is to lower the recurrence and progression rates of cancer and increase the survival rate by administering Immuncell-LC in combination with gemcitabine, the standard treatment for refractory pancreatic cancer.
Immuncell-LC received product approval as an anti-cancer drug for liver cancer in 2007. In 2015, the results of a Phase 3 clinical trial involving 230 liver cancer patients were published in the gastroenterology journal ‘Gastroenterology’, attracting global attention.
When Immuncell-LC was administered to patients with stage 4 pancreatic cancer, it showed a 25% response rate and a progression-free survival (PFS) of 11 weeks. Its potential as a second-line anti-cancer therapy was confirmed. It has been evaluated as a treatment method that utilizes the patient’s own immune cells, resulting in fewer side effects and taking into account the patient’s quality of life.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
